Intravitreal bevacizumab was associated with improved visual acuity in most treated eyes.
Bevacizumab for choroidal neovascularization related to inflammatory diseases.
Michal Kramer … Radgonde Amer
Retina (Philadelphia, Pa.) · Jun 2010 · Q1 in Ophthalmology
Purpose
The purpose of this study was to report our experience with intravitreal bevacizumab for inflammation-related choroidal neovascularization in two tertiary centers.
Methods
This study was a retrospective analysis of patients with choroidal neovascularization related to inflammatory diseases, treated with intravitreal bevacizumab injections (1.25 mg/0.05 mL).
n = 10 patients
9
Results
9
of 10 eyes
eyes had better measured vision after treatment
n = 10 patients
More results
Seven patients received additional treatment based on the underlying condition.
Mean macular thickness on optical coherence tomography decreased from 394 +/- 116 microm to 254 +/- 52 microm (P < 0.01).
More results
Mean visual acuity improved from 0.87 +/- 0.74 logarithm of the minimum angle of resolution to 0.38 +/- 0.63 (P = 0.005).
“
Conclusion
Intravitreal bevacizumab is an effective treatment for choroidal neovascularization related to inflammatory diseases when inflammation is controlled.
